Cancer cells are different from normal cells, as normal cells can result in generation of cancerous cells, when a series of mutations leads the normal cell to continue to grow and divide out of control. Cancer cells have the ability to travel or invade nearby tissues and thus spread to different regions of body, unlike normal cells that remain in the region, where they began. Cancer cells are generated in the human body through a series of genetic and epigenetic changes. Some of these changes may be either inherited or more often, caused by carcinogens (cancer causing substances) such as tobacco and others.
The global cancer cell market is estimated to be valued at US$ 8,525.5 million in 2020 and is expected to exhibit a CAGR of 8.20 % during the forecast period (2020-2027).
Figure 1. Global Cancer Cell Market Value (US$ Mn), 2016-2027
Increasing prevalence of cancers such as lung cancer, breast cancer, and others is expected to propel growth of the global cancer cell market during the forecast period. For instance, according to the World Health Organization report published in 2018, stated that cancer is the second leading cause of death in people globally and caused around 9.6 million deaths, globally in the year 2018.
Furthermore, key companies focusing on inorganic strategies such as mergers and acquisitions to launch new targeted cell therapies for the treatment of people suffering from cancer, are expected to drive growth of the market. For instance, in 2018, Pfizer, Inc. announced its merger with Allogene to develop an investigational CAR-T cell therapy for the treatment of cancer.
Cancer Cell Market Report Coverage
|Base Year:||2019||Market Size in 2020:||US$ 8,525.5 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||8.20 %||2027 Value Projection:||US$ 8,525.5 Mn|
Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare.
|Restraints & Challenges:||
Global Cancer Cell Market – Impact of Coronavirus (COVID-19)
Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in over 67 million infected individuals worldwide as of December 07, 2020.
The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted the financial status of major companies in cancer cell market. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic. The pandemic has negatively impacted the global cancer cell market in various aspects such as research and development, production, and supply of medicines and also affected growth of the pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries. The nationwide lockdowns have led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the raw materials and drugs for therapeutic use.
Figure 2. Global Cancer Cell Market Share (%), By Region, 2020
North America is expected to hold dominant position in the global cancer cell market during the forecast period, owing to key companies focusing on inorganic strategies such as mergers and acquisitions for developing the treatment of various cancers such as lung cancer and others. For instance, in August 2020, Siemens Healthineers announced its merger with Varian Medical Systems, a manufacturer of radiation therapy hardware and software to build out its cancer care offerings and provide a screening platform and diagnosis for the better and efficient treatment for cancer.
Major players operating in the global cancer cell market include Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare.
Frequently Asked Questions